Takeda Pharmaceutical (TAK) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Which has higher valuation & earnings, GMAB or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	8.29	$631.91M	$1.20	24.98
Takeda Pharmaceutical	$28.20B	1.48	$994.06M	$0.55	24.04

Does the media prefer GMAB or TAK?

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 3 mentions for Genmab A/S. Takeda Pharmaceutical's average media sentiment score of 0.57 beat Genmab A/S's score of 0.24 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer GMAB or TAK?

Genmab A/S currently has a consensus price target of $48.50, indicating a potential upside of 61.77%. Takeda Pharmaceutical has a consensus price target of $14.00, indicating a potential upside of 5.90%. Given Takeda Pharmaceutical's higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more risk & volatility, GMAB or TAK?

Genmab A/S has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Takeda Pharmaceutical has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

Do insiders & institutionals believe in GMAB or TAK?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community favor GMAB or TAK?

Genmab A/S received 42 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 60.68% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 142 60.68%	Underperform Votes 92 39.32%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of 6.18%. Takeda Pharmaceutical's return on equity of 18.90% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	30.74%	18.90%	16.83%
Takeda Pharmaceutical	6.18%	9.92%	4.71%

Summary

Genmab A/S beats Takeda Pharmaceutical on 13 of the 17 factors compared between the two stocks.